BMS finally gets FDA OK for liso-cel, sets $410k launch priceBristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share XBMS finally gets FDA OK for liso-cel, sets $410k launch pricehttps://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/
NICE reverses stance on Celgene’s Revlimid for myeloma maintenanceNHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after Share XNICE reverses stance on Celgene’s Revlimid for myeloma maintenancehttps://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/
BMS/Celgene merger payout evaporates as CVR deadline passesFormer Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three Share XBMS/Celgene merger payout evaporates as CVR deadline passeshttps://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/
Fresh doubts over BMS’ merger payout as FDA delays key drug reviewHolders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out Share XFresh doubts over BMS’ merger payout as FDA delays key drug reviewhttps://pharmaphorum.com/news/fresh-doubts-over-bms-merger-payout-as-fda-delays-key-drug-review/
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor Share XCould an FDA inspection scupper CVR deadline for BMS’ liso-cel?https://pharmaphorum.com/news/could-an-fda-inspection-scupper-cvr-deadline-for-bms-liso-cel/
FDA’s review date for BMS’ ide-cel sneaks under the CVR wireThe FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, Share XFDA’s review date for BMS’ ide-cel sneaks under the CVR wirehttps://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/
Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel fileThe chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right Share XCelgene investors’ CVR payment looks rocky, as FDA rejects ide-cel filehttps://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/
Concerns over BMS and Celgene merger payout as FDA extends drug reviewBristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be Share XConcerns over BMS and Celgene merger payout as FDA extends drug reviewhttps://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/
BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
